Erlanger Cardiology completed the first in Chattanooga concomitant left atrial appendage closure (LAAC) and cardiac ablation ...

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated ...

The first-in-human trial is taking place at Na Homolce hospital in Prague, Czech Republic, and will treat up to 50 patients.

The China 3D cardiac mapping market has showcased significant growth, with its valuation increasing from $55.55 million in 2019 to a projected $150.59 million by 2027. This report offers a detailed ...

In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the ...

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...